KTTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pasithea Therapeutics Corp (KTTA) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows bearish technical indicators, no significant trading signals, and lacks positive catalysts. Additionally, the financial performance is weak, with negative EPS and net income despite some YoY improvement in losses. Given the absence of strong growth prospects or positive sentiment, it is better to hold off on investing in this stock.
The technical indicators for KTTA are bearish. The MACD is slightly positive but contracting, RSI is neutral at 43.756, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 0.753, with support at 0.699 and resistance at 0.806.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
The stock is in a bearish trend with a 70% chance of declining further (-0.51% in the next day, -2.69% in the next week, -7.44% in the next month). Financial performance remains weak, with negative EPS and net income.
In Q4 2025, revenue remained at 0 with no YoY growth. Net income improved YoY but remains negative at -10,110,868. EPS dropped significantly by -68.77% YoY to -0.79. Gross margin is 0, indicating no profitability.
No data available on analyst ratings or price target changes.
